One the first point, Meaning there are patient
Post# of 148216
(Total Views: 383)
Posted On: 08/14/2019 7:25:25 AM
Re: Stramboat19 #6094
One the first point,
JMO, but 700mg will always give more coverage, so there are not people that fail at 700mg but succeed at 525mg. The 525mg looks better because it weeded out more failures before 10 weeks.
My view, which could be wrong, is there is a range of receptor ccr5 count per cell, that they find is very successful with 525mg. Then above that range, they give the 700mg. Now they might also find the 700mg has a range and above that they don't enroll in mono. So they increase the overall efficacy of both doses.
But there is another issue, there is a small group of people, that occupancy spikes during the trial. That group might be identified via dna, not sure, but Patterson has created an array of tests.
https://www.cytodyn.com/newsroom/press-releas...ab-pro-140
Recent discussions with Dr. Bruce K. Patterson, CEO and Founder of IncellDx, Inc. and a top expert in CCR5, has revealed that through certain laboratory tests looking at the genetics and expression of CCR5 in individual patients, CytoDyn may more closely match the most effective dose for each HIV monotherapy patient to achieve viral suppression.
Quote:
Meaning there are patients that fail at 700 who would succeed at 525 and there are patients that fail at 525 who will succeed at 700. Hope so.
JMO, but 700mg will always give more coverage, so there are not people that fail at 700mg but succeed at 525mg. The 525mg looks better because it weeded out more failures before 10 weeks.
My view, which could be wrong, is there is a range of receptor ccr5 count per cell, that they find is very successful with 525mg. Then above that range, they give the 700mg. Now they might also find the 700mg has a range and above that they don't enroll in mono. So they increase the overall efficacy of both doses.
But there is another issue, there is a small group of people, that occupancy spikes during the trial. That group might be identified via dna, not sure, but Patterson has created an array of tests.
https://www.cytodyn.com/newsroom/press-releas...ab-pro-140
Recent discussions with Dr. Bruce K. Patterson, CEO and Founder of IncellDx, Inc. and a top expert in CCR5, has revealed that through certain laboratory tests looking at the genetics and expression of CCR5 in individual patients, CytoDyn may more closely match the most effective dose for each HIV monotherapy patient to achieve viral suppression.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼